SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is trending following news of its Snapdragon Ride Pilot system launching in BMW's iX3, highlighting increased automotive revenue and a push into ADAS. The community is discussing the potential for this and upcoming Snapdragon Summit announcements to drive the stock higher, with some eyeing a move towards long-term resistance levels. Bullish sentiment is fueled by Qualcomm's attractive valuation compared to its peers.

Energy Fuels, Inc. is a mining development company, which engages in the exploration and evaluation of uranium and vanadium properties. It also operates the Nichols Ranch, Alta Mesa, and White Mesa Mill projects. The company was founded by George E. L. Glasier and John David Mason on June 24, 1987 and is headquartered in Lakewood, CO.

Energy Fuels Inc

Energy Fuels is trending amid discussions around rare earth elements and a recent deal with Australia, potentially positioning the company to benefit from efforts to reduce reliance on China. Community members are actively debating the impact of this deal, analyzing options flow, and speculating on potential catalysts such as government contracts, with some expressing concerns about dilution. Technical analysis and trading strategies are also being heavily discussed, with many participants closely watching for key price levels.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

UAMY is trending as investors discuss its volatile price action and potential acquisition of Larvotto Resources, with some expressing concerns about valuation and dilution. Community members are weighing the impact of US-China trade relations and the company's strategic position in antimony production, particularly in light of government contracts and expansion plans. Bullish investors are accumulating shares, anticipating future growth and potential government support for UAMY's role in securing domestic supply chains.

Click Holdings Ltd. operates as a holding company which provides temporary and permanent personnel solutions. Its services include professional solution services, nursing solution services, and logistics and other solution services. The company was founded by Chan Chun Sing on January 31, 2024 and is headquartered in Hong Kong.

Click Holdings Ltd. - Ordinary Shares - Class A

Click Holdings Limited

Click Holdings (CLIK) is trending due to renewed trading momentum following a report of strong revenue growth, sparking discussions of a potential short squeeze given its low float. The community is weighing the impact of insider ownership and potential for high volatility. Some traders are highlighting the stock's potential for significant gains, while others caution about its history and risk of dilution.

🔥 COCK Token – The Ultimate Cross-Chain MemeFi Powerhouse 🔥  In just under 20 days, $COCK has smashed expectations, broken ATHs, and built a project that’s shaking up Cardano and the entire crypto space. 🐓 What Makes $COCK Special?      The Name: Love it or hate it, the energy and engagement it generates are undeniable. The nuance in language and wild appeal set us apart.     #MEMEFI Pioneer: We’re not just another meme coin. $COCK is leading a movement by combining DeFi mechanics, game theory, and community engagement into a groundbreaking ecosystem.     COCKARENA: At the core of our ecosystem is the COCKARENA, a PvP HODL game. Players battle it out, and early exit fees fuel redistributions, burns, and the treasury. This ensures price appreciation and long-term sustainability for loyal holders.  🎰 The COCK Casino  Our casino isn’t just fun—it’s a serious revenue stream for the FLOCK.      Games: Bonanza, Crash, Blackjack, and Roulette (coming soon!).     Impact: Over 7,834 ADA in profits generated within days, directly supporting rewards, burns, and reinvestment.  💰 COCK-ARENA Loans  Unlock liquidity without selling your tokens.      Loan Terms: Borrow up to 30% of your holdings while continuing to earn rewards in the arena.     Investor Focus: Perfect for savvy investors staying in the game while tapping into their holdings.  🤝 Our Insane Partnerships  We’re bridging gaps, building alliances, and breaking barriers across the crypto space. Key Partners:      DANZO: Powering #MEMEFI with Arena, Casino, and Loans.     KLENEK: Interactive training room.     HSKN (Charles Hoskilien): Supporting and starting COCKPIN with 115 AIR NODES for DePIN aggregation. Plans to add APEX and Earth Nodes through a crypto company incorporated in Costa Rica.     ELITE CATS / SNEKKIES / HOT / BANK: Rewarding NFT holders with COCK-LOCK tokens and vice versa.     OCKZ: COCKSOCKS, Golden Cock Ticket (1M COCK), airdrop rewards, and whitelist perks for holders of 200 ADA worth of $COCK.     OLI Partnership:         Content Creation: Lux and the team are crafting engaging educational content about memes and MemeFi for OLi's platform.         Strategic Investment: The OLi Community Trust will invest in $COCK, distributing 100% of rewards to $OLI holders.         Community Reach: Over 22,000 learners will discover $COCK through OLi's gamified ecosystem.     Hi-Rez the Rapper: Expanding reach in marketing and entertainment.     KUNO, CALEB, CADEN, FITY, ROVER, WhaleInsider: Influential collaborators driving crypto adoption and growth.     Cardano Girls: Helping us understand and communicate effectively with ADA’s female audience.     WallStreetBets: Breaking barriers and increasing engagement.     Antonio Brown: Endorsing, supporting, and even playing in the casino and arena!     Advisors:         BERIS, HECKTHESNEK, RTB, CRYPTOGENIUS: Trusted names advising and supporting the project.  Future Partnerships:  More collaborations are in the pipeline to continue expanding engagement and bring new eyes to ADA and CNTs. 🔥 Unmatched Results in Just 20 Days      Supply Burned: 1.65%, worth 148K ADA!     Arena Fees Collected: 54M COCK, worth over 500K ADA, fueling rewards, burns, and partnerships.     Staked COCK-LOCK: 11M COCK-LOCK in the liquid staking platform, with more coming.     Casino Revenue: Skyrocketing profits directly rewarding holders and growing the treasury.     Top Blast Contests: Generated over 120K ADA in volume, rewarding participants with over 50K ADA in prizes.  🌍 Our Vision  To be the most decentralized, rewarding, and innovative token on Cardano while fostering cross-chain collaboration and onboarding the masses.      Breaking Barriers: We’re bringing BTC, ETH, SOL, and other chains into the fold.     Community-Driven: Focused on building bridges and showcasing that crypto can be fun, rewarding, and sustainable.     Expansion: This is just the beginning. With more burns, rewards, and partnerships on the way, $COCK is set to redefine what’s possible in the MemeFi space.  💎 Time in the arena > Timing the market. The FLOCK is unstoppable. Let’s keep breaking walls for Cardano and onboard new users as we take $COCK to new heights.

CockCardano

CockCardano ($COCK) is trending as the community rallies around its real-world asset, Cocky Wings LLC, a food truck business that fuels buybacks. Discussions highlight the project's unique MemeFi ecosystem on Cardano, with many flocking to its arena for passive rewards and revenue-generating potential. The partnership with $SNEK energy drinks is also generating excitement.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is trending as the stock plunges following a pause in clinical trials due to a patient developing liver problems, sparking discussions about the safety of gene editing and its impact on the sector. While some investors are concerned about the potential long-term implications, others view the overreaction as a buying opportunity, emphasizing the long-term potential of CRISPR technology and the company's pipeline. Community members are debating whether the trial pause is a temporary setback or a more serious issue, with some pointing to the patient's age and BMI as contributing factors.

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include SyndAccess, Revuforj, Niktimvo, and IncyteCARES. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.

Syndax Pharmaceuticals Inc

SNDX is trending as investors discuss its potential in the menin inhibitor space alongside competitor KURA, weighing its two FDA-approved drugs and revenue against KURA's upcoming PDUFA. Community members are highlighting SNDX's high short interest, potential buyout scenarios, and upcoming earnings as factors driving current interest. Some traders are debating the impact of FDA label expansion and a boxed warning on future growth.

Infinite Money Glitch ($IMG) is revolutionizing DeFi on Solana by leveraging the Token2022 program's advanced tax extension capabilities to create a truly innovative reward system for token holders.  At its core, $IMG implements a seamless 5% tax on all transactions - whether buying, selling, or transferring tokens. This tax is automatically collected and distributed to holders in SOL, creating a sustainable passive income stream for the community. 4.5% of the tax gets sent to holders, while .5% gets sent to an Infrastructure wallet to help with development, marketing and general infrastructure.  What sets $IMG apart is its implementation of Solana's Token2022 program, enabling automated and efficient reward distribution without relying on external smart contracts.

Infinite Money Glitch

IMG Crypto is trending as the community buzzes about passive income opportunities through holding and earning Solana rewards. Discussions highlight the project's ongoing development, including participation in a Solana hackathon, and the potential for transparent, community-driven growth within the DeFi space. Some users express skepticism, while others voice strong conviction in the project's long-term potential and unique reward system.

DZZ provides -2x the daily performance of futures contracts relating to gold. The notes index selects contracts based on the shape of the futures curve to minimize contango.

Deutsche Bank AG London - DB Gold Double Short ETN

PowerShares DB Gold Double Short ETN

DZZ is trending due to discussions around potential gains as a double short gold ETF, with community members pointing to gold's struggles and anticipating further downward movement. Some traders highlight technical indicators suggesting a possible squeeze, while others reference broader market conditions and their potential impact on gold prices. Overall, the sentiment leans towards DZZ benefiting from a bearish outlook on gold.

Unusual Machines, Inc. is a development stage technology company, which engages in the provision of drone solutions with a focus on first-person view (FPV) technology. It offers products to entertainment, recreation, and competitive racing industries. The company was founded on July 11, 2019, and is headquartered in Orlando, FL.

Unusual Machines Inc

Unusual Machines, Inc.

Unusual Machines is trending due to a newly announced $800,000 order for drone components from Red Cat Holdings. The community is discussing the significance of this order, particularly the motors that will power Red Cat's FANG drones, and what it means for UMAC's position in the defense and government drone markets. Some are speculating about larger contracts on the horizon and the potential for further growth in the drone sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Phathom Pharmaceuticals (PHAT) Upgraded to Buy: Here's Why

Phathom Pharmaceuticals (PHAT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Wall Street Analysts See a 66.13% Upside in Phathom Pharmaceuticals (PHAT): Can the Stock Really Move This High?

The mean of analysts' price targets for Phathom Pharmaceuticals (PHAT) points to a 66.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Think Phathom Pharmaceuticals (PHAT) Could Surge 87.21%: Read This Before Placing a Bet

The consensus price target hints at an 87.2% upside potential for Phathom Pharmaceuticals (PHAT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Phathom Pharmaceuticals, Inc. (PHAT) Reports Q2 Loss, Tops Revenue Estimates

Phathom Pharmaceuticals (PHAT) delivered earnings and revenue surprises of -3.95% and +8.94%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

MannKind (MNKD) Reports Break-Even Earnings for Q2

MannKind (MNKD) delivered earnings and revenue surprises of -100.00% and -2.58%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Krystal Biotech, Inc. (KRYS) Tops Q2 Earnings and Revenue Estimates

Krystal Biotech (KRYS) delivered earnings and revenue surprises of +19.44% and +6.12%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Wall Street Analysts Believe Phathom Pharmaceuticals (PHAT) Could Rally 107.4%: Here's is How to Trade

Phathom Pharmaceuticals shares soar on FDA exclusivity grant

Investing.com -- Shares of Phathom Pharmaceuticals Inc. (NASDAQ: PHAT) soared 128% after the FDA granted the company’s petition for exclusivity in the Orange Book listing for its drug Voquezna (vonoprazan fumarate). The decision by the Food and Drug Administration to extend the exclusivity period to a full 10 years for Voquezna, under the umbrella of the Generating Antibiotic Incentives Now (GAIN) provisions, has been a significant catalyst for the stock’s movement.

​Retail interest for Phathom Pharmaceuticals soared on Thursday after the company reported first-quarter results, unveiled a sweeping cost-reduction plan and reaffirmed its target to achieve operational profitability by 2026.The company posted Q1 revenue of $28.5 million, slightly below the $29.02 million consensus.&nbsp;Its net loss widened to $94.3 million from $82.9 million a year earlier, driven largely by increased advertising and promotional spend for its lead drug, VOQUEZNA.“2025 will be an inflection point for Phathom,” said CEO Steve Basta.&nbsp;The company announced a 6% workforce reduction, multiple leadership changes, and significant cuts in external spending.&nbsp;Phathom expects the moves to reduce 2025 operating expenses by $60 million to $70 million and lower quarterly spend to under $55 million by the fourth quarter.Basta said the company’s actions are designed to support long-term growth without raising new equity or debt. He added that sales force strength remains a top priority, with commercial personnel now comprising around 75% of the total workforce.Voquezna prescriptions rose 8% sequentially in Q1 to 127,000, while cumulative prescriptions surpassed 390,000 as of April 18.&nbsp;Commercial access remained strong, with coverage extending to over 120 million lives, including more than 80% of commercially insured patients.Phathom also paused its planned Phase 2 trial for eosinophilic esophagitis and is awaiting an FDA decision on its citizen petition seeking full NCE exclusivity through 2032.Retail traders on Stocktwits remained optimistic despite the revenue miss, with sentiment marked as ‘bullish’ amid a 900% surge in 24-hour messaging volume.&nbsp;Several users said they were buying the dip, expressing continued confidence in the company’s long-term prospects.<stembedurl>https://stocktwits.com/DrDare/message/613236534</stembedurl>One user said the volume spike was notable but still lower than on days when major patent or executive updates had occurred.&nbsp;<stembedurl>https://stocktwits.com/Morrito23/message/613282417</stembedurl>They noted persistent concerns over cash burn, but said they welcomed management's move to finally address the issue publicly.Some traders described the first quarter as unusually difficult for pharmaceutical firms, citing formulary changes and deductible resets.&nbsp;Others saw the update as a turning point, with one saying the stock could become a buyout candidate if exclusivity concerns are resolved and revenue momentum continues.<stembedurl>https://stocktwits.com/Canvasback33/message/613238887</stembedurl>Shares of Phanthom have fallen 54.2% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Packaging and pills of different types of psychotropic medications are seen in this illustration photo taken in Warsaw, Poland on 22 April, 2025. (Photo by Jaap Arriens/NurPhoto via Getty Images)

Retail Interest in Phathom Soars As Firm Pledges Profit Path, Cuts Costs After Q1 Miss

Phathom's VOQUEZNA prescriptions rose 8% sequentially in Q1, with over 390,000 cumulative fills and expanding adoption across both GI and primary care. 

Equity

Phathom's Voquezna prescriptions rose 8% sequentially in Q1, with over 390,000 cumulative fills and expanding adoption across both GI and primary care. 


2 Growth Stocks to Buy Now With 367% to 410% Upside

Strong, innovative pipelines make these two biotech firms smart buys now.

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ.

Phathom Pharmaceuticals Inc

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

PHAT
Phathom Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest PHAT News

PHATPhathom Pharmaceuticals Inc